In this study, we analyzed the effect of endothelin-1 (ET-1) on expression of the lectin-like oxidized lowdensity lipoprotein (oxLDL) receptor-1 LOX-1 and on oxLDL uptake in primary cultures of human umbilical vein endothelial cells (HUVEC). LOX-1 mRNA was quantified by standard-calibrated competitive RT-PCR, LOX-1 protein expression by Western analysis and endothelial oxLDL uptake using DiI-labeled ox-LDL. ET-1 induces LOX-1 mRNA expression, reaching its maximum after 1 h (160 ؎ 14% of control, 100 nM ET-1, P < 0.05). This increased ET-1-mediated LOX-1 mRNA expression could be inhibited by endothelin receptor B antagonist BQ-788. In addition, ET-1 stimulates LOX-1 protein expression and oxLDL uptake in HUVEC. The augmented oxLDL uptake by ET-1 is mediated by endothelin receptor B, but not by protein kinases. These data support a new pathophysiological mechanism how locally and systemically increased ET-1 levels could promote LOX-1-mediated oxLDL uptake in human endothelial cells and the development and progression of endothelial dysfunction and atherosclerosis.
Endothelin-1 (ET-1) has been suggested to be involved in the pathogenesis of cardiovascular diseases (1). ET-1 plasma level is increased in patients with hypertension and coronary artery disease, but in several other pathophysiological conditions as well. In addition, augmented local ET-1 concentration has been described in atherosclerotic plaques (2, 3) . Furthermore, endothelin receptor blockade was shown to reduce the development of atherosclerotic lesions in experimental studies (4) .
Another potent risk factor in the development and progression of atherosclerosis is oxidatively modified low-density lipoprotein (oxLDL) (5) . In the early phase of atherosclerosis, oxLDL impairs endothelial relaxation (6) by reduction of endothelial NO synthase expression and induction of vascular generation of reactive oxygen species (7, 8) . OxLDL induces endothelial expression of adhesion molecules (9) and increases endothelial apoptosis (10) . In later phases of atherosclorosis, oxLDL is internalized by macrophages via scavenger receptors leading to foam cell formation.
Endothelial cells mediate the uptake of oxLDL by the recently cloned lectin-like oxLDL receptor-1 (LOX-1) (11), which is accumulated in atherosclerotic lesions (12) . In addition, the LOX-1 receptor was shown to mediate endothelial phagocytosis of aged and apoptotic cells (13) . LOX-1 can be induced by tumor necrosis factor-␣, phorbol 12-myristate 13-acetate, shear stress and transforming growth factor ␤ (14 -16).
Recently, angiotensin II (Ang II) has been shown to induce LOX-1 in human endothelial cells (17, 18) . Therefore, LOX-1 has been suggested to provide a link between hypertension and atherogenesis (19) . However, the impact of the potent vasoconstrictor ET-1 on the expression of LOX-1 is currently unknown. Therefore we analyzed the effect of ET-1 on LOX-1 expression and oxLDL uptake in primary cultures of human umbilical vein endothelial cells (HUVEC).
MATERIALS AND METHODS
Cell culture. All cell culture reagents and chemicals were purchased from Sigma Chemical Co. if not indicated otherwise. Primary cultures of human umbilical vein endothelial cells (HUVEC) were isolated with collagenase IV as previously described (20) . In order to minimize variations of primary cultures, each day the isolated endothelial cells were pooled and subsequently separated in medium M199 with 1.25 g/L sodium bicarbonate, 100 mg/L L-glutamine (Life Technologies), supplemented with 20% calf serum, 15 mmol/L Hepes, 100,000 U/L penicillin, 100 mg/L streptomycin, 250 mg/L fungizone (Life Technologies), and 16.7 g/L endothelial cell growth supplement (C. C. Pro, Neustadt, Germany). Confluent cell cultures were incubated with medium containing 0.5% calf serum for 24 h and subsequently treated with ET-1 (1-100 nmol/L).
Quantification of LOX-1 mRNA expression. Total RNA from endothelial cells was isolated by guanidinium thiocyanate/cesium chloride centrifugation (21) . Quantification of LOX-1 mRNA expression by standard calibrated competitive reverse transcriptasepolymerase chain reaction (RT-PCR) by use of an internal-deleted LOX-1 standard was done as previously described (18) . PCR products were separated by standard agarose gel electrophoresis with ethidium bromide and documented by photography using Polaroid film type 665. The optical density of the amplified PCR fragments was quantified by scanning using a laser-densitometer and computer-based imaging system (Molecular Dynamics, Sunnyvale, CA). Optical density of standard PCR fragments was normalized vs. sample specific PCR fragments with a correction coefficient (bp target / bp standard ϭ 579 bp/468 bp ϭ 1.24). Using the SigmaPlot scientific graphing software (Jandel Corp, San Rafael, CA), the logarithm of the quotient of normalized standard and sample specific PCR fragment density was graphically plotted vs the respective standard dilutions. In the graph, the equivalence point represents equal amounts of RNA molecules in sample and standard.
Western blot analysis. After stimulation, HUVEC were washed with cold phosphate-buffered saline (pH 7.2) and resuspended in lysis buffer (10 mmol/L Tris-HCl, pH 7.4; 2% SDS; Complete Boehringer protease inhibitor) followed by an incubation at 95°C for 10 min. Lysates were cleared of particulates by centrifugation at 5000g for 10 min at 4°C and stored at Ϫ80°C. Protein concentration was determined using the BCA protein assay (Pierce, Rockford, IL). Samples containing 50 g of total protein were mixed with 2ϫ loading buffer (250 mmol/L Tris-HCl, pH 7.4; 20% glycerol; 4% SDS; 40 mmol/L DTT; 2 mmol/L Na-EDTA; 0.1% bromphenol blue), boiled for 2 min, and loaded onto a 10% SDS-polyacrylamide gel. Proteins were transferred to PVDF membranes by electroblotting, blocked with 8% nonfat dry milk in TBST (200 mmol/L Tris-HCl, pH 7.5; 300 mmol/L NaCl; 0.1% Tween 20) at room temperature for 40 min, and incubated with a primary human LOX-1 antibody at room temperature for 3 h. Blots were subsequently washed in TBST and incubated with specific peroxidase-coupled secondary antibodies (Amersham Pharmacia Biotech, Buckinghamshire, UK). Bound antibodies were detected by enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech, Buckinghamshire, UK), quantified using a laser-densitometer with imaging system (Molecular Dynamics, Sunnyvale, CA), and normalized to the densitometrically determined amount of total protein loading per lane after Coomassie blue staining of the corresponding polyacrylamide gel.
Uptake of DiI-oxLDL in human endothelial cells. Low density lipoprotein (LDL) was isolated by sequential ultracentrifugation from human plasma, and oxidative modification of LDL with cupric ion was carried out as previously described (22) . Oxidized LDL was labeled with 1,1Ј-dioctadecyl-3,3,3Ј,3Ј-tetramethylindocarbocyanine perchlorate (DiI, Molecular Probes). Confluent primary cultures of HUVEC were incubated with medium containing 0.5% serum for 24 h, stimulated with ET-1 (100 nmol/L) for the indicated times, and incubated with DiI-labeled oxLDL (100 g/mL, 3 h). The cells were washed 5 times with medium containing 0.5% serum, DiI-labeled oxLDL extracted with 2-propanol, and fluorescence was measured (520/564 nm). The protein concentration of each sample was determined using Bio-Rad DC Protein Assay, and used to normalize fluorescence values as previously described (18). 
RESULTS

Upregulation of LOX-1 Expression by ET-1 in Human Endothelial Cells
ET-1 induces LOX-1 mRNA expression in human endothelial cells (max. 1 h: 160 Ϯ 14% of control, 100 nmol/L ET-1, n ϭ 5, P Ͻ 0.05) (Fig. 1) . The LOX-1 mRNA induction by ET-1 is dose-dependent reaching its maximum at 100 nmol/L (Fig. 2) . Next, we performed experiments in order to identify the endothelin receptor, which is involved in the induction of LOX-1. The induction of LOX-1 mRNA by ET-1 could be prevented by the ET B receptor antagonist BQ-788 (1 mol/L) (Fig. 3) .
In order to verify these findings on the protein level, expression of LOX-1 protein was quantified by Western blot analysis. Incubation of HUVEC with ET-1 (100 nmol/L) induced LOX-1 protein expression (max. 1 h: 171 Ϯ 21% of control, n ϭ 5, P Ͻ 0.05) (Fig. 4) .
ET-1 Induces Endothelial OxLDL Uptake by an ET B -Dependent Mechanism in HUVECs
In order to evaluate the functional significance of augmented LOX-1 mRNA and protein expression, uptake of DiI-labeled oxLDL was quantified after ET-1 stimulation in HUVECs. ET-1 induces oxLDL uptake in HUVECs (max. 1 h: 223 Ϯ 29% of control, 100 nmol/L ET-1, n ϭ 9, P Ͻ 0.05) (Fig. 5) . Therefore, ET-1 induces LOX-1 mRNA and protein expression to a similar level like oxLDL uptake (approximately 2-fold).
In independent experiments, the impact of specific endothelin receptor blockade and of protein kinases on ET-1 stimulated oxLDL uptake was analyzed. The augmented oxLDL uptake by ET-1 is mediated by the endothelin receptor B (Fig. 6A) . In contrast, the protein kinase inhibitor H7 (10 mol/L) (Fig. 6B ) had no effect on the ET-1-stimulated oxLDL uptake in human endothelial cells. Similar results were obtained using the protein kinase C-specific inhibitor RO-31-8220 (1 mol/L).
DISCUSSION
In this study, ET-1 induces LOX-1 mRNA and protein expression in a time-and dose-dependent manner in human endothelial cells. This is accompanied by a similar increase in ET-1-mediated oxLDL uptake. Therefore, our data suggest a LOX-1-mediated oxLDL uptake in endothelial cells in response to ET-1. This is supported by our data that induction of LOX-1 expression and functional oxLDL uptake by ET-1 is mediated by the ET B receptor. Because human endothelial cells almost exclusively express the ET B receptor (23, 24) , proatherosclerotic effects of ET-1 in endothelial cells should be mediated by ET B . An additional ET Bmediated proatherosclerotic mechanism is the upregulation of endothelial superoxide anion formation by induction of NAD(P)H oxidase (25) . In this way, ET-1 could enhance oxidative modification of LDL to oxLDL and furthermore increase uptake of oxLDL in endothelial cells in vivo.
The increased uptake of oxLDL could result in endothelial dysfunction by impaired endothelium-dependent arterial relaxation (6), infiltration of the vessel wall with monocytes/macrophages by increased endothelial expression of adhesion molecules (9) , and secretion of growth factors for vascular smooth muscle cells resulting in vascular hypertrophy (26) . Other early proatherosclerotic effects of oxLDL would include delay of endothelial wound healing (27) , e.g., by inhibition of migration of aortic endothelial cells into endothelial lesions (28) , cytotoxicity to vascular cells (29) , e.g., through induction of oxidative stress (8) , and induction of apoptosis in endothelial cells (10) . Therefore, ET-1-stimulated oxLDL uptake in endothelial cells could be involved in early proatherosclerotic processes, before macrophages participate in the progression of atherosclerosis. Because LOX-1 expression has been described in mature human monocyte-derived macrophages (30), increased ET-1 levels might accelerate foam cells formation by LOX-1-mediated oxLDL uptake in endothelial cells and macrophages.
In addition, oxLDL could further promote a proatherosclerotic circulus vitiosus in vivo by augmenting ET-1 release and increased superoxide anion formation in arterial vessels (22) . This potentiation by ET-1 might involve augmented superoxide anion formation in vascular smooth muscle cells and macrophages mediated by endothelin receptor A in later phases of atherosclerosis (31) .
Therefore, this study further supports the view, that LOX-1-mediated oxLDL uptake provides a missing link between hypertension and atherosclerosis (19) . Locally and systemically increased ET-1 levels, e.g., in hypertension, could promote LOX-1-mediated oxLDL uptake in human endothelial cells. This mechanism could accelerate the development and progression of endothelial dysfunction and atherosclerosis. Furthermore, endothelin receptor blockade might provide a new antiatherosclerotic therapeutic principle.
FIG. 6.
The increased oxLDL uptake in response to ET-1 is mediated by an ET B receptor-dependent pathway in HUVECs. ET-1 augments uptake of DiI-labeled oxLDL in HUVECs by an endothelin receptor B-mediated mechanism (A). In contrast, the pathway of ET-1-stimulated oxLDL uptake does not involve protein kinases (B). The oxLDL uptake after incubation with ET-1 (dashed bars) is indicated as percentage of internal control without ET-1 incubated with or without BQ-788 (A) or H7 (B) (white bars) (n ϭ 4 each, *P Ͻ 0.05 vs control).
